文献速递胸部肿瘤

表现为影像学部分实性结节的肺腺癌定义一种特殊临床亚型

Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype.
PubMed 文献 · J Thorac Oncol · 2019-01-17

该回顾性研究在复旦大学附属肿瘤医院比较了部分实性结节、纯磨玻璃结节与纯实性肿瘤的临床病理特征和生存,共分析911例患者988个肺结节。部分实性结节患者淋巴转移率低于纯实性肿瘤(2.2% vs 27%),5年肺癌特异性无复发生存和总生存介于纯磨玻璃结节与纯实性肿瘤之间。实性成分占比、实性成分大小和肿瘤大小可预测病理浸润性腺癌但不能预测预后。

要点

  • 部分实性结节患者淋巴转移率2.2%,低于纯实性肿瘤的27%。
  • 部分实性结节5年生存介于纯磨玻璃结节与纯实性肿瘤之间。
  • 亚肺叶切除与肺叶切除预后相当,系统性淋巴结清扫与否预后差异无统计学意义。

核心结论

  • 部分实性肺腺癌的临床病理特征不同于纯实性肿瘤。
  • 实性成分占比、实性成分大小和肿瘤大小不能预测部分实性肺腺癌的预后。
  • 部分实性肺腺癌定义一种特殊临床亚型。

研究设计与样本

  • 回顾性比较部分实性肿瘤与纯磨玻璃结节及纯实性肿瘤的临床病理特征和生存时间。
  • 研究对象为在复旦大学附属肿瘤医院接受手术治疗的肺结节患者,共911例患者、988个肺结节。
  • 评估实性成分占比、实性成分大小和肿瘤大小对部分实性肺腺癌的预后意义。

主要发现

  • 共分析988个肺结节,包括329个部分实性结节、501个纯磨玻璃结节和158个纯实性结节。
  • 部分实性结节中女性患者更多(p=0.015)、非吸烟者更多(p=0.003),均多于纯实性结节。
  • 部分实性结节患者淋巴转移率为2.2%,低于纯实性肿瘤患者的27%(p<0.001)。
  • 部分实性结节患者的5年肺癌特异性无复发生存和总生存差于纯磨玻璃结节患者(p<0.001和p=0.042),但优于纯实性肿瘤患者(p<0.001和p<0.0001)。
  • 实性成分占比(OR=12.90;95%CI:1.85-90.04)、实性成分大小(OR=1.45;95%CI:1.28-1.64)和肿瘤大小(OR=1.23;95%CI:1.15-1.31)可预测部分实性结节患者的病理浸润性腺癌,但均不能预测预后。

关键数值与推荐

  • 部分实性结节患者接受亚肺叶切除的预后与接受肺叶切除者相当(5年肺癌特异性无复发生存p=0.178,5年肺癌特异性总生存p=0.319)。
  • 接受系统性淋巴结清扫与未接受系统性淋巴结清扫患者之间的预后差异无统计学意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The clinicopathologic features and prognostic predictors of radiological part-solid lung adenocarcinomas were unclear. METHODS: We retrospectively compared the clinicopathologic features and survival times of part-solid tumors with those of pure ground glass nodules (pGGNs) and pure solid tumors treated with surgery at Fudan University Shanghai Cancer Center and evaluated the prognostic implications of consolidation-to-tumor ratio (CTR), solid component size, and tumor size for part-solid lung adenocarcinomas. RESULTS: A total of 911 patients and 988 pulmonary nodules (including 329 part-solid nodules [PSNs], 501 pGGNs, and 158 pure solid nodules) were analyzed. More female patients (p = 0.015) and nonsmokers (p = 0.003) were seen with PSNs than with pure solid nodules. The prevalence of lymphatic metastasis was lower in patients with PSNs than in those with pure solid tumors (2.2% versus 27% [p < 0.001]). The 5-year lung cancer-specific (LCS) recurrence-free survival and LCS overall survival of patients with PSNs were worse than those of patients with pGGNs (p < 0.001 and p = .042, respectively) but better than those of patients with pure solid tumors ([p < 0.001 and p < 0.0001, respectively]). CTR (OR = 12.90; 95% confidence interval [CI]: 1.85-90.04), solid component size (OR = 1.45; 95% CI: 1.28-1.64), and tumor size (OR = 1.23; 95% CI: 1.15-1.31) could predict pathologic invasive adenocarcinoma for patients with PSNs. None of them could predict the prognosis. Patients receiving sublobar resection had prognoses comparable to those of patients receiving lobectomy (p = .178 for 5-year LCS recurrence-free survival and p = .319 for 5-year LCS overall survival). The prognostic differences between patients with systemic lymph node dissection and those without systemic lymph node dissection were statistically insignificant. CONCLUSIONS: Part-solid lung adenocarcinoma showed clinicopathologic features different from those of pure solid tumor. CTR, solid component size, and tumor size could not predict the prognosis. Part-solid lung adenocarcinomas define one special clinical subtype.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ye T, Deng L, Wang S, et al. Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype. J Thorac Oncol. 2019. PMID: 30659988. doi:10.1016/j.jtho.2018.12.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。